A New Jefferson's Reserve Cask Strength Release Is Simple And Elegant
Jefferson's Reserve Cask Strength
Elevate Business Photography
Jefferson's Bourbon is probably best known in some circles for its ocean-aged and finished whiskeys. Its newest release aims to create a memorable pour with a more straightforward approach: unfiltered, uncut Kentucky straight bourbon whiskey, blended and bottled at cask strength.
Jefferson's Reserve Cask Strength is a limited-time version of Jefferson's Reserve, a bourbon that's served as the brand's flagship for years. The brand calls it a 'high-proof evolution of the iconic Jefferson's Reserve.' After an early taste (more on that below), we can say the resulting whiskey is bold, fruity, and accessibly drinkable, even at its high proof. The bourbon ultimately rides a fine line between brightness and oak.
Like the flagship and always-available release, Jefferson's Reserve Cask Strength is a marriage of sourced Kentucky bourbons, with blending overseen by Founder and Master Blender Trey Zoeller. But while Jefferson's Reserve is bottled at 90.2 proof, this cask strength release topped out at 130 proof (65% ABV) after blending was complete. According to the brand, the youngest bourbon in the blend is eight years old.
Jefferson's was founded in 1997, a joint project between Kentucky native Zoeller and his father Chet, a respected and well-known bourbon historian. The brand was among the first to popularize sourced and blended American whiskeys. Today, some of its earlier bottlings—especially the Presidential Select series—remain among the most celebrated releases of the early 'Bourbon Boom' period from around 2008 through 2015. Its Jefferson's Ocean line started as an experiment to age bourbon casks at sea and has since become a hallmark of the brand.
Pernod Ricard acquired the brand in 2019, and Zoeller stayed on in a directing and blending capacity; today he remains heavily involved in new product development.
'With this cask strength release, we're peeling back the layers to reveal the whiskey in its most authentic form—untamed, uncut, and packed with intense flavor,' said Zoeller in a company press release.
We had a chance to try Jefferson's Reserve Cask Strength for ourselves. The nose is big and bold, with a sweet, confectionary nose that matches the whiskey's 130 proof almost punch-for-punch. A medley of spiced fruit cobblers lead—think peach, apple, and berry topped with golden brown dough and sprinkled with cinnamon—followed by rum-soaked raisins and cherry cough drops.
While there's plenty of ethanol on the nose (though it's never overpowering), the palate isn't as hot as one might expect. Instead, more fruit leads, especially maraschino cherries. That quickly transitions into vanilla cherry cola and raspberry compote. The finish leans into cream soda, oak tannins, and a hint of chocolate truffles. That oak is both noticeable and restrained, and Jefferson's was pretty clearly intentional releasing this at eight years; the whiskey rides a fine line between fruity, peppery youth and tannins that become dominant as most bourbon approaches the decade mark.
Jefferson's Reserve Cask Strength is a limited time offering, available as of April across the United States. It carries an MSRP of $69.99 for a 750 mL bottle.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
2 hours ago
- Newsweek
NATO Ally Looks to Buy US Nuclear-Capable Fighter Jets to Counter Russia
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The United Kingdom is hoping to purchase American-made fighter jets, capable of both carrying and deploying nuclear weapons, according to a report in The Sunday Times. The British newspaper cited anonymous senior officials familiar with the matter, who said the U.K. intends buying Lockheed Martin F-35A Lightning stealth fighter aircraft, but that other options are also being evaluated. The Sunday Times reported that the potential deal was part of the country's broader strategy to address threats posed by Russia, and that the "highly sensitive" talks between the Pentagon and the Ministry of Defence have been led by Admiral Sir Antony David Radakin, head of the UK's armed forces, and Secretary of State for Defence John Healey. When contacted for comment, the Ministry of Defence directed Newsweek to an interview given by Healey on Sunday morning, in which he said that such discussions "are not conducted in public," but refused to rule out whether the purchase was an option. Why It Matters Combined with other actions taken and statements made by the U.K. government in recent days, including tomorrow's release of the 2025 Strategic Defence Review, the purchase would signal a significant escalation in Britain's assessment of the threats posed by Russia and the urgency of countering these. Additionally, Prime Minister Keir Starmer has recently set out plans to increase the country's defense budget to 2.5 percent of its gross domestic product (GDP) by 2027, up from the current 2.3 percent. This follows calls from NATO officials for member states to devote a greater portion of their budget to counter Russian threats, and similar requests from President Donald Trump What To Know According to the U.S. Air Force, the F-35A Lightning possesses a range of more than 1,350 miles and is capable of carrying payloads of up to 18,000 pounds. Variants of the F-35 have already been certified to carry B61-12 thermonuclear gravity bombs, a type of low-yield nuclear munitions. Having decommissioned its stockpile of tactical, air-delivered nuclear weapons following the end of the Cold War, the U.K. has relied on its "Trident" system as a nuclear deterrent. The arsenal is exclusively capable of being deployed by four Royal Navy Vanguard-class submarines. A U.S. Air Force fifth generation F-35A Lightning II stealth aircraft comes in to land outside RAF Lakenheath on April 17, 2025 in Lakenheath, England. A U.S. Air Force fifth generation F-35A Lightning II stealth aircraft comes in to land outside RAF Lakenheath on April 17, 2025 in Lakenheath, Sunday Times report comes ahead of the release of the government's strategic defence review, which Healey told the BBC would send a "message to Moscow." In a briefing released ahead of the full report, the government said the review would outline a "total commitment to the UK's nuclear deterrent," as well as a "NATO-first" defence policy." What People Are Saying Secretary of State for Defence John Healey spoke to Sky News about the reported purchase on Sunday morning, saying: "Those sort of discussions are not conducted in public and certainly not with a running commentary." "I want to make a wider point though on our nuclear deterrent which is this: For nearly 70 years, our U.K. nuclear deterrent has been the guarantor of our U.K. security—it's what Putin fears most," he added. "And the threats we face in the future, mean we will always have to do what we need to defend the country, and strong deterrence is absolutely essential in order to keep Britain and the British people safe." Lord De Mauley, chair of the Lords International Relations and Defence Committee, said in October: "Years of strategic neglect have left our forces stretched thin and limited in size. We are underprepared to respond to the worsening global threat environment, and in particular to meet the very real and growing threat from Russia." UK Prime Minister Keir Starmer, in an article for The Sun published Sunday, said his government was committed to restoring "Britain's war-fighting readiness." He cited the emergence of "new nuclear risks," as well as cyberattacks orchestrated by Russia alongside Iran and North Korea. What Happens Next? The government's Strategic Defence Review 2025 is scheduled for publication on Monday.
Yahoo
2 hours ago
- Yahoo
VNET Group First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Revenue: CN¥2.25b (up 18% from 1Q 2024). Net loss: CN¥237.6m (loss widened by 27% from 1Q 2024). CN¥0.89 loss per share (further deteriorated from CN¥0.71 loss in 1Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) missed analyst estimates. Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the IT industry in the US. Performance of the American IT industry. The company's shares are down 11% from a week ago. We should say that we've discovered 3 warning signs for VNET Group (2 can't be ignored!) that you should be aware of before investing here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
2 hours ago
- Yahoo
Do Merit Medical Systems' (NASDAQ:MMSI) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. Sometimes these stories can cloud the minds of investors, leading them to invest with their emotions rather than on the merit of good company fundamentals. Loss making companies can act like a sponge for capital - so investors should be cautious that they're not throwing good money after bad. Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like Merit Medical Systems (NASDAQ:MMSI). While profit isn't the sole metric that should be considered when investing, it's worth recognising businesses that can consistently produce it. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. If a company can keep growing earnings per share (EPS) long enough, its share price should eventually follow. So it makes sense that experienced investors pay close attention to company EPS when undertaking investment research. It certainly is nice to see that Merit Medical Systems has managed to grow EPS by 34% per year over three years. As a general rule, we'd say that if a company can keep up that sort of growth, shareholders will be beaming. Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. Merit Medical Systems maintained stable EBIT margins over the last year, all while growing revenue 8.2% to US$1.4b. That's a real positive. In the chart below, you can see how the company has grown earnings and revenue, over time. Click on the chart to see the exact numbers. View our latest analysis for Merit Medical Systems The trick, as an investor, is to find companies that are going to perform well in the future, not just in the past. While crystal balls don't exist, you can check our visualization of consensus analyst forecasts for Merit Medical Systems' future EPS 100% free. We would not expect to see insiders owning a large percentage of a US$5.6b company like Merit Medical Systems. But we do take comfort from the fact that they are investors in the company. Notably, they have an enviable stake in the company, worth US$132m. Holders should find this level of insider commitment quite encouraging, since it would ensure that the leaders of the company would also experience their success, or failure, with the stock. If you believe that share price follows earnings per share you should definitely be delving further into Merit Medical Systems' strong EPS growth. With EPS growth rates like that, it's hardly surprising to see company higher-ups place confidence in the company through continuing to hold a significant investment. On the balance of its merits, solid EPS growth and company insiders who are aligned with the shareholders would indicate a business that is worthy of further research. However, before you get too excited we've discovered 1 warning sign for Merit Medical Systems that you should be aware of. There's always the possibility of doing well buying stocks that are not growing earnings and do not have insiders buying shares. But for those who consider these important metrics, we encourage you to check out companies that do have those features. You can access a tailored list of companies which have demonstrated growth backed by significant insider holdings. Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
